Oesophageal cancer ranks seventh in cancer incidence and sixth in cancer-related mortality worldwide. East Asia is the leading high incidence area of oesophageal cancer, which suffers from the most predominant burden comprising more than half of incident cases and deaths globally. Treatment for oesophageal cancer has been evolving quickly, especially with the rapid development of minimally invasive techniques, constant optimization of chemo-radiation therapeutic regimens, and the increasing clinical trials of innovative targeted therapy and immunotherapy, However, the clinical prognosis is still frustrating, with a 5-year survival rate ranged 10% - 20%.
Given the above concerns, an in-depth understanding of a series of putative risk factors or protective factors that can be precisely predictive of post-therapeutic prognosis has become particularly pivotal to help to settle more individualized treatment schedules for the high-risk patients with oesophageal cancer. Researchers have paid increasing attention to identifying safe, convenient, and promising prognostic predictors, and further create innovative scoring systems by integrating these parameters reasonably to contribute to a precise risk assessment for adverse events, survival, recurrence, and metastasis of patients with oesophageal cancer.
This Research Topic aims to provide insights into the emerging prognostic factors and prediction models that can be easily and objectively obtained during peri-therapeutic procedures and further significantly refine the precise risk stratification for post-therapeutic outcomes in patients with oesophageal cancer. We welcome Original Research, Reviews, Mini Reviews, and Clinical Trials addressing the clinical implications of potential prognostic tools related but not limited to peripheral blood testing, immune-nutritional status, medical imaging, operations, postoperative care, histologic or molecular characteristics of oesophageal cancer.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Oesophageal cancer ranks seventh in cancer incidence and sixth in cancer-related mortality worldwide. East Asia is the leading high incidence area of oesophageal cancer, which suffers from the most predominant burden comprising more than half of incident cases and deaths globally. Treatment for oesophageal cancer has been evolving quickly, especially with the rapid development of minimally invasive techniques, constant optimization of chemo-radiation therapeutic regimens, and the increasing clinical trials of innovative targeted therapy and immunotherapy, However, the clinical prognosis is still frustrating, with a 5-year survival rate ranged 10% - 20%.
Given the above concerns, an in-depth understanding of a series of putative risk factors or protective factors that can be precisely predictive of post-therapeutic prognosis has become particularly pivotal to help to settle more individualized treatment schedules for the high-risk patients with oesophageal cancer. Researchers have paid increasing attention to identifying safe, convenient, and promising prognostic predictors, and further create innovative scoring systems by integrating these parameters reasonably to contribute to a precise risk assessment for adverse events, survival, recurrence, and metastasis of patients with oesophageal cancer.
This Research Topic aims to provide insights into the emerging prognostic factors and prediction models that can be easily and objectively obtained during peri-therapeutic procedures and further significantly refine the precise risk stratification for post-therapeutic outcomes in patients with oesophageal cancer. We welcome Original Research, Reviews, Mini Reviews, and Clinical Trials addressing the clinical implications of potential prognostic tools related but not limited to peripheral blood testing, immune-nutritional status, medical imaging, operations, postoperative care, histologic or molecular characteristics of oesophageal cancer.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
